world-biotechnology-2017-keynote

7 / 8

Page 46
Notes:
conferenceseries .com
Volume 7, Issue 6 (Suppl) J Biotechnol Biomater, an open access journal
ISSN: 2155-952X World Biotechnology 2017
December 04-05, 2017
2nd World Biotechnology Congress
December 04-05, 2017 | Sao Paulo, Brazil
Recombinant proteins from bench to clinics
Recombinant proteins from the use of DNA technology are found in essentially every western pharmacy, medical testing
laboratory, and biological research laboratory. One major issue regarding the clinical use of many peptides is their short
half-life due to the rapid clearance from the circulation. To overcome this problem, we succeeded to ligate the signal sequence of
O-linked oligosaccharides to the coding sequence of the hormones. The cassette gene that has been used contains the sequence
of the carboxyl-terminal peptide (CTP) of human chorionic gonadotropin β (hCGβ) subunit. The CTP contains 28 amino
acids with four O-linked oligosaccharide recognition sites. It was postulated that O-linked oligosaccharides add flexibility,
hydrophilicity and stability to the protein. On the other hand it was suggested that the four O-linked oligosaccharides play an
important role in preventing plasma clearance and thus increasing the half-life of the protein in circulation. Using this strategy,
we succeeded to ligate the CTP to the coding sequence of follitropin (FSH), thyrotropin (TSH), erythropoietin (EPO) growth
hormone (GH) and thus to increase the longevity and bioactivity of these proteins in-vivo. Interestingly, the new analogs of
FSH and GH were found not immunogenic in human and it is already passed successfully clinical trials phase III and phase II
respectively. Moreover, FSH long acting was approved by the European Commission (EC) for treatment of fertility. In addition,
our results indicated that long acting GH is not toxic in monkeys and the results from clinical trials phase I and phase II seem
to be promising. Designing long acting peptides will diminish the cost of these drugs and perhaps reduce the number of
injections in the clinical protocols
Biography
Fuad Fares has completed his DSc studies at the Faculty of Medicine, Technion-Israel Institute of Technology, and Postdoctoral studies at the Department of
Molecular Biology and Pharmacology, School of Medicine, Washington University, St. Louis Missouri. He is the Director of the Department of Molecular Genetics
at Carmel Medical Center and Associated Professor at the Department of Human Biology, University of Haifa. He has published more than 75 papers in reputed
journals and serving as a Member of the Israel Council for Higher Education. He is the inventor of designing long-acting recombinant proteins and the initiator of
PROLOR Biotech company.
Fuad Fares
University of Haifa, Israel
Fuad Fares, J Biotechnol Biomater 2017, 7:6 (Suppl)
DOI: 10.4172/2155-952X-C1-084